MDMA Facts
Stimulant;
Description
MDMA (3,4-methylenedioxy-N-methylamphetamine) — ecstasy, molly — is a synthetic empathogen of the substituted amphetamine class. It floods the brain with serotonin, norepinephrine, and dopamine, producing emotional warmth rather than stimulant energy.[1][2]
Subjective effects include euphoria, intense warmth toward others, sociability enhancement and trust, and mild brightening of perception.[3] The experience is defined by its entactogenic quality — profound emotional openness and closeness to others unlike either stimulant energy or psychedelic expansion.
MDMA produces no physical dependence, though moderate psychological dependence is documented;[4] no human lethal dose has been established. The main dangers — overheating, dangerous sodium imbalance, and serotonin syndrome — multiply sharply in hot environments and when combined with serotonin-active drugs.[2]
Dose and durationby route · individual sensitivity varies
Starts in 30 – 45 minLasts 3 – 6 hoursAfter-effects 12 – 48 hours
Body and dependence
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Physical dependence
- Low
- Psychological dependence
- Moderate
- Withdrawal
- Mild
- Compulsive redosing
- Moderate
Tolerance
- Builds
- Rapid
- Fully resets after
- 75 days
- Carries over to
- MDA;
MDEA; 5-APB; 6-APB; methylone; mephedrone; amphetamine
Effectslikely at a common dose
- Perception
- Touch enhancement;
Music enhancement; Dreaming suppression; Auditory enhancement; +11 possible, including Visual haze / noise - Body
- Appetite suppression;
Dry mouth; Temperature dysregulation; Excessive sweating; Wakefulness; Pupil dilation; Spontaneous body sensations; Stimulation; Bruxism; Muscle tension; Body high; Body scan awareness; Insomnia; Physical fatigue; Tactile euphoria; Tingling / electric sensations; +25 possible, including Dehydration sensation, Vasoconstriction, Abnormal heartbeat - Thinking
- Cognitive fatigue;
Immersion enhancement; Cognitive euphoria; Aesthetic enhancement; Introspection enhancement; Openness enhancement; +29 possible, including Compulsive redosing urge, Cognitive impairment, Decision impairment - Feeling
- Anxiety suppression;
Emotional enhancement; Empathy enhancement; Euphoria; +9 possible, including Depression, Emotional lability, Anhedonia - Self
- Disinhibition;
Social connection; Communication enhancement; Emotional susceptibility; Sociability enhancement; Trust enhancement; +7 possible, including Craving, Social disconnection, Derealization - Time
- none likely · 3 possible, including Temporal disorientation
- Transpersonal
- none likely · 1 possible
- Awareness
- Personal insight;
+3 possible
Who shouldn't take it
Combinations65 recorded
Seek help immediately if
- Overheating / very high body temperature — heavy sweating, then hot dry skin (the leading cause of MDMA deaths, worse when dancing in hot venues)
- Muscle rigidity, jaw clenching, tremor, or twitching (possible serotonin syndrome)
- Fast, pounding heartbeat; chest pain
- Agitation, confusion; seizures
- Hyponatremia (water intoxication) — headache, confusion, drowsiness, vomiting, and seizures from drinking too much water
- Nausea/vomiting; collapse or unconsciousness
What to do
- Move them somewhere cool and help them cool down — overheating is the main danger
- Sip water to stay hydrated but DO NOT overdrink — roughly a cup (250 ml) per hour if active; too much water can be deadly (hyponatremia)
- Get them to rest and stop dancing
- For overheating, seizures, chest pain, muscle rigidity/tremor, confusion, or unresponsiveness, call emergency services
- Recovery position if drowsy or vomiting; stay with them
- Be ready to give rescue breaths / CPR
Most resolve with cooling, rest, sensible hydration, and time. The life-threatening dangers are hyperthermia, serotonin syndrome, and hyponatremia (too much water) — each a medical emergency, not something to wait out.
988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE
References
- [1]^Pifl C, Nagy G, Berényi S, et al. (2005) Pharmacological characterization of ecstasy synthesis byproducts with recombinant human monoamine transporters — Journal of Pharmacology and Experimental Therapeutics PMID:15831439
- [2]^abGreen AR, Mechan AO, Elliott JM, O'Shea E, Colado MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") — Pharmacological Reviews doi:10.1124/pr.55.3.3
- [3]^Cami J, Farré M, Mas M, et al. (2000) Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects — Journal of Clinical Psychopharmacology PMID:10917407
- [4]^Syed OA, Nestor SM, Husain MI, et al. (2026) Adverse events associated with classic psychedelics and MDMA: a real-world population-based study using WHO pharmacovigilance database (VigiBase) — Psychiatry Research doi:10.1016/j.psychres.2025.116929